Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Fulvestrant, marketed under the brand name Faslodex, is a potent selective estrogen receptor downregulator (SERD) utilized primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women. Unlike traditional aromatase inhibitors that merely block estrogen production, Fulvestrant functions by binding directly to the estrogen receptor with high affinity, inducing a conformational change that destabilizes the receptor protein. This interaction triggers rapid degradation of the receptor via the ubiquitin-proteasome pathway, effectively reducing both the quantity and function of estrogen receptors within cancer cells. By eliminating these critical drivers of tumor growth, Fulvestrant halts the proliferation of hormone-dependent breast cancer cells.
The chemical identity of Fulvestrant is defined by its molecular formula, C31H47FO3S, and it carries the unique CAS registry number 129453-61-8. Structurally, it belongs to the steroidal class of compounds, featuring a complex steroid backbone modified with specific functional groups that enhance its specificity for the estrogen receptor while minimizing off-target effects. The drug is administered exclusively via deep intramuscular injection due to its poor oral bioavailability, typically following a loading dose regimen on days 1, 15, and 29, followed by monthly maintenance doses.
Clinical applications have expanded beyond first-line therapy; it is now frequently employed as an endocrine therapy option after progression on other hormonal treatments or in combination with CDK4/6 inhibitors like palbociclib or ribociclib for initial management of advanced disease. While generally well-tolerated, common side effects include hot flashes, nausea, injection site reactions, and fatigue. Serious adverse events may involve thromboembolic events or hepatic enzyme elevations. As a cornerstone in the evolving landscape of precision oncology, Fulvestrant represents a significant advancement over older anti-estrogens like tamoxifen, offering a mechanism that actively depletes rather than just blocks the target receptor, thereby providing a robust therapeutic strategy for patients with hormone-driven malignancies. Its continued integration into global treatment guidelines underscores its vital role in extending survival and improving quality of life for women battling this prevalent form of cancer.